Vitiligo in Uniform — Same Disease, Different System (ep. 77)

Ten percent. That's how the U.S. Department of Veterans Affairs rates vitiligo when it affects exposed skin. Zero percent when it doesn't. Simple enough on paper. But what does that actually mean for veterans living with vitiligo, and how do you navigate the VA system to get the benefits you may be entitled to? In this episode of Deep Dive in Vitiligo, we take a practical look at VA disability benefits for vitiligo. We explain how the rating system works, walk through the main steps of filing a claim, and outline the medical records, supporting evidence, and paperwork that can help make your case. Along the way, we explore why the impact of vitiligo on military careers, mental health, and everyday life isn't always reflected in a disability percentage. In this episode, we discuss: The 10% rule: How the VA rates vitiligo and what qualifies for compensation. Filing a claim: The main steps, eligibility requirements, and what to expect along the way. Getting your paperwork right: Medical records, service connection evidence, photographs, and other supporting documentation. Beyond the rating: What to consider when vitiligo affects mental health, work, or quality of life. Whether you're preparing your first VA claim, trying to understand an existing rating, or simply wondering what support is available, this episode offers a clear starting point without drowning you in government jargon. Because ten percent may be the number on the paperwork. It doesn't have to be the whole story.  

Take a look inside your bathroom cabinet. Every prescription cream, every medicine you rely on, has a story behind it. Somewhere along the way, someone volunteered for a clinical trial, accepted a little uncertainty, and helped make that treatment possible. Most of us will never know their names. But we all benefit from their decisions. For someone living with vitiligo, joining a clinical trial may offer access to an experimental treatment, expert medical care, and a chance to help develop better therapies for everyone. But there's a practical side to that decision: time off work, missed school, long journeys to the clinic, extra tests, and perhaps giving up a cream that's finally helping. All without any guarantee of improvement. In this episode of Deep Dive in Vitiligo, we explore the opportunities, uncertainties, and everyday realities of clinical research, drawing on VRF resources, conversations at the recent Vitiligo Leadership Forum in Goa, India, and lessons from patient recruitment. In this episode, we discuss: Why clinical trials matter: How today's volunteers make tomorrow's treatments possible. The hidden costs of participation: Travel, time, family responsibilities, and the logistics of fitting research into real life. Placebos and uncertainty: Why existing treatments sometimes need to be paused and why results can never be guaranteed. Parents and children: Why deciding for your child can be harder than deciding for yourself. What makes people say yes or no: And how VRF's new multilingual survey aims to understand those decisions. Clinical trials need volunteers, but volunteers have lives beyond the clinic. Our goal isn't to persuade everyone to enroll. It's to help people make informed choices and researchers design studies that more patients can realistically join. After all, someone helped make the treatments in your bathroom cabinet possible. Perhaps one day, someone else will be grateful you did the same.    

Pregnancy has a way of ignoring project plans. Add vitiligo to the mix, and suddenly Google becomes a scary place full of outdated advice and medical catastrophizing. In this episode of Deep Dive in Vitiligo, we take a honest, scientifically grounded look at what happens to your skin before, during, and after baby arrives. From medication safety and postpartum flares to thyroid checks and genetic inheritance myths, we’re cutting through the noise with reassuring, practical answers every mom-to-be needs to hear. In this episode, we discuss: How pregnancy actually affects vitiligo activity (and why most women stay stable) What the latest studies say about pregnancy risks and thyroid health Navigating topicals, light therapy, and new treatments like Opzelura The real genetic odds of passing vitiligo to your child Whether you’ve been carefully planning for months or just stared in shock at a positive test on a Tuesday morning, pull up a chair—this is your ultimate, no-panic guide to navigating pregnancy with vitiligo. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode: Pregnancy and Vitiligo

A paused drug program. A reasonable suspicion. Then the question under it: why is there still no cure? In this episode, Yan Valle argues there is no hidden pill in a glass tower. Companies are not charities, and they are not sitting on a cure because a chronic treatment pays better. The harder account is ordinary. Academia funds what it can publish. Biotech bets on the next round. Pharma keeps what can survive the regulators and the market. Insurers pay for this year’s budget. Patients inherit the sum. A program can die before anyone knows if the biology was right — a bet on another bet, ten years out, before the casino is built. Early treatment of active vitiligo sounds obvious, and still loses to step therapy and a planning horizon shorter than a child’s year. The price on the receipt was not set by one hand. And “they buried the cure” is easier to air than a system with no villain. Misconduct is real. This is not a defense of it. But systems before conspiracy is usually the better place to start. The full essay is on the VRF site. Ten minutes. A double coffee is welcome.

Your skin may enter the room first. Your job is to make sure your work takes over the conversation. Visible vitiligo does not change competence. It can still change interviews, promotions, and how “professional” gets judged — especially when the face is involved. That is a social problem, not a skills problem. Social problems need strategy, boundaries, and sometimes a little documentation. In this episode we cover the unglamorous playbook: how to build a case instead of a vibe, what to say if someone stares or asks the wrong question, when disclosure helps and when it doesn’t, and which workplace protections may apply in the US and the UK. Bias exists. So do portfolios, notes, and the right to leave. Your skin is not the product. Prefer reading to listening? The companion article expands on the themes in this episode: Career Success with Visible Vitiligo.

Fifteen years ago, keeping up with vitiligo news was easy. There simply wasn’t that much of it. Today, research, clinical trials, industry updates, patient discussions, and AI-generated answers arrive faster than anyone can realistically process them. In Episode 78 of Deep Dive in Vitiligo, we look at what happens next: people stop searching, comparing, and opening twenty browser tabs — and start asking AI to do the thinking for them. That shift has a name: cognitive surrender. We explore why handing part of the decision-making process to ChatGPT and other AI tools can be perfectly rational, where it becomes risky, and why pharma companies, doctors, and patient organizations suddenly need to care about what AI says when someone asks a very simple question: “What are my options?” AI may be both the cause of the information flood and our best tool for navigating it. Just don’t let it out of the fire pit. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode. 15 Years of Vitiligo News Publication

What changes when vitiligo puts on a uniform? The disease stays the same. Almost everything around it changes — from medical fitness and deployment to treatment access, military records, VA care, and disability claims. In this episode of Deep Dive in Vitiligo, we follow the patient journey from sick call to civilian care and examine where people, records, and responsibility can fall through the cracks. We also separate three questions that are too often mixed together: Can someone join? Can they remain in service? And did military service cause or aggravate the condition? We close with a preview of Massé World’s Honor Without Exception, a free symposium bringing service members, veterans, clinicians, researchers, and policymakers together in Miramar, Florida, on November 14, 2026. Same skin condition. Different rules. Much higher stakes. 📚 Prefer reading to listening? The full companion article expands on many of the themes discussed in this episode.

Durante años, la crema aprobada se detenía a los 12. Los más pequeños se quedaban con el menú de siempre: corticoides, tacrolimus, luz si había hueco, y mucha espera. Eso empieza a cambiar. Hay dos ensayos de fase 3 con crema de ruxolitinib — Opzelura, si ya conoces el tubo — en niños con la forma más común de vitíligo. Protocolos de verdad. Centros de verdad. No un rumor de un grupo de padres. El matiz: no son el mismo estudio. Si los mezclas, una familia reserva viaje al continente equivocado. En este episodio de *Deep Dive in Vitiligo* ponemos los dos ensayos uno al lado del otro. Vas a escuchar: El ensayo norteamericano TRuE-ViP (NCT06548360): de 2 a 11 años, Estados Unidos y Canadá, unos 180 niños El ensayo internacional (NCT06804811, Incyte INCB18424-309): a partir de los 6 años, Argentina más 13 países europeos, unos 250 niños, sin centros en EE. UU. ni Canadá Lo que comparten: solo vitíligo no segmentario, un techo del 10% de superficie corporal, crema vehículo las primeras 24 semanas, la cara como medida principal en la semana 24, y la obligación de pausar otros tratamientos para el vitíligo, incluida la fototerapia Por qué un niño de 8 años puede cumplir la edad en los dos y no encajar en ninguno por código postal No suspendas un tratamiento que ya funciona porque en la misma semana aparecieron dos páginas de ensayo. Pregunta en el centro qué habría que pausar. Después llama al dermatólogo habitual del niño. Sí es una respuesta razonable. No también. La pregunta útil es qué protocolo — si es que alguno — encaja con este niño, en este país, con esta agenda.    

For years, approved ruxolitinib cream has stopped at age 12. Younger children have had a much shorter menu: steroids, tacrolimus, light therapy if you can get a slot, and a lot of waiting. Now two Phase III studies are evaluating ruxolitinib cream in younger children. Its use for vitiligo in these age groups is investigational — researchers are still finding out how well it works and how safe it is. Real protocols. Real sites. Not a rumor from a parent group. Then the catch: they are not the same study. Mix them up and a family books the wrong continent. In this episode of Deep Dive in Vitiligo, we put the trials side by side. You’ll hear: North American trial TRuE-ViP (NCT06548360) — ages 2 to 11, United States and Canada The international trial (NCT06804811, Incyte INCB18424-309) — starts at age 6, Argentina plus 13 European countries, no U.S. or Canadian sites What they share: nonsegmental vitiligo, a 10% body-surface ceiling, active-versus-vehicle treatment during the first 24 weeks, facial scoring at Week 24, and some restrictions. Why an 8-year-old can fit both studies by age and neither by postcode. Do not stop a working routine because two trial pages appeared in the same week. Ask the site what would pause. Then call the child’s regular dermatologist. Yes is a reasonable answer. No is a reasonable answer. The useful question is which protocol — if either — fits this child, in this country, with this schedule. Both studies discussed in this episode are sponsored by Incyte Corporation. VRF provides patient education and study-awareness support related to Incyte pediatric vitiligo research under a paid services agreement. VRF does not determine study eligibility or recommend participation. 📚 Prefer reading to listening? These two companion articles expand on many of the themes discussed in this episode. Vitiligo Study For Children Ages 2–11 in USA and Canada  Vitiligo Study For Children Ages 6-11, International

Most people think gloves are simple: put them on, protect your hands, move on with life. Unfortunately, your skin didn’t get that memo. In this episode of Deep Dive in Vitiligo, we explore the surprisingly complicated world of work gloves, hand dermatitis, chemical leukoderma, and the Koebner phenomenon. Why do some gloves trigger itching, cracking, or irritation? Why can friction matter almost as much as chemicals? And why are many dermatologists quietly steering patients toward accelerator-free nitrile gloves? We compare latex, vinyl, and nitrile options, discuss cotton and silk liners, tackle the rise of biodegradable “eco-friendly” gloves, and explain how a simple choice at the hardware store or workplace can affect long-term hand health. No fear-mongering. No glove industry conspiracies. Just practical advice to help your hands do their job without becoming part of the problem. Because the best glove is supposed to protect your skin — not give it a new hobby.  📚 Prefer reading to listening? The companion article expands on many of the themes discussed in this episode.